Gindri Izabelle de Mello, Ferrari Gustavo, Pinto Luiz Paulo S, Bicca Juliana, Dos Santos Isis Kelly, Dallacosta Darlan, Roesler Carlos Rodrigo de Mello
bio meds Pharma, Florianópolis, Brazil.
Nimma, Federal University of Santa Catarina, Florianópolis, Brazil.
Am J Physiol Endocrinol Metab. 2024 Apr 1;326(4):E417-E427. doi: 10.1152/ajpendo.00242.2023. Epub 2023 Nov 16.
Nicotinamide adenine dinucleotide (NAD) is an essential pyridine nucleotide cofactor that is present in cells and in several important biological processes, including oxidative phosphorylation and production of adenosine triphosphate, DNA repair, calcium-dependent secondary messenger and gene expression. The purpose of this systematic review is to examine whether the coenzyme formulae NAD and NADH are safe and effective when acting as a supplement to humans. This systematic review of randomized clinical trials performed a search in six electronic databases: PubMed, MEDLINE (), Embase, Cochrane CENTRAL (clinical trials), Web of Science, and Scopus. Secondary search included the databases (e.g., Clinical trials.gov, Rebec, Google Scholar - advance). Two reviewers assessed and extracted the studies independently. The risk of bias in studies was performed using version 2 of the Cochrane risk of bias tool for randomized trials. This review includes 10 studies, with a total of 489 participants. The studies included different clinical conditions, such as chronic fatigue syndrome (CFS), older adults, Parkinson's disease, overweight, postmenopausal prediabetes, and Alzheimer's disease. Based on studies, the supplementation with NADH and precursors was well tolerated and observed clinical results such as, a decrease in anxiety conditions and maximum heart rate was observed after a stress test, increased muscle insulin sensitivity, insulin signaling. Quality of life, fatigue intensity, and sleep quality among others were evaluated on patients with CFS. All studies showed some side effects, thus, the most common associated with NADs use are muscle pain, nervous disorders, fatigue, sleep disturbance, and headaches. All adverse events cataloged by the studies did not present a serious risk to the health of the participants. Overall, these findings support that the oral administration of NADH can be associated to an increase in general quality of life and improvement on health parameters (e.g., a decrease in anxiety, maximum heart rate, inflammatory cytokines in serum, and cerebrospinal fluid). NADH supplementation is safe and has a low incidence of side effects. Future investigations are needed to evidence the clinical benefits regarding specific diseases and doses administered.
烟酰胺腺嘌呤二核苷酸(NAD)是一种必需的吡啶核苷酸辅酶,存在于细胞中,并参与多个重要的生物过程,包括氧化磷酸化和三磷酸腺苷的生成、DNA修复、钙依赖性第二信使以及基因表达。本系统评价的目的是研究辅酶形式的NAD和NADH作为人体补充剂时是否安全有效。本对随机临床试验的系统评价在六个电子数据库中进行了检索:PubMed、MEDLINE()、Embase、Cochrane CENTRAL(临床试验)、科学网和Scopus。二次检索包括其他数据库(如Clinical trials.gov、Rebec、谷歌学术高级版)。两名评价者独立评估并提取研究。使用Cochrane随机试验偏倚风险工具第2版对研究中的偏倚风险进行评估。本评价纳入了10项研究,共489名参与者。这些研究包括不同的临床情况,如慢性疲劳综合征(CFS)、老年人、帕金森病、超重、绝经前糖尿病前期和阿尔茨海默病。基于研究,补充NADH及其前体耐受性良好,并观察到一些临床结果,如压力测试后焦虑状况和最大心率降低、肌肉胰岛素敏感性增加、胰岛素信号增强。对CFS患者的生活质量、疲劳强度和睡眠质量等进行了评估。所有研究均显示出一些副作用,因此,与使用NAD相关的最常见副作用是肌肉疼痛、神经紊乱、疲劳、睡眠障碍和头痛。研究记录的所有不良事件对参与者的健康均未构成严重风险。总体而言,这些发现支持口服NADH可提高总体生活质量并改善健康参数(如焦虑减轻、最大心率降低、血清和脑脊液中的炎性细胞因子减少)。补充NADH是安全的,副作用发生率低。未来需要进行研究以证明特定疾病和给药剂量的临床益处。